|Healthcare Review: Venaxis Inc, MiMedx Group, Alexion Pharmaceuticals, Rockwell Medical, pSivida Corp.|
|By Staff and Wire Reports|
|Monday, 15 July 2013 14:20|
Venaxis Inc. (NASDAQ:APPY) shares declined 5.65% to $1.30. The company on July 15 announced that the external Data and Safety Monitoring Board (DSMB) created as part of the Company's pivotal clinical trial for the APPY1 Test has recommended continuation of the pivotal clinical trial, based upon completion of the first of two futility analyses included in the clinical trial design. Venaxis will host a conference call and webcast tomorrow morning, July 16, 2013, at 8:30 a.m. ET, to discuss the DSMB's recommendation and to provide a general corporate update.
MiMedx Group Inc. (NASDAQ:MDXG) stock dropped 6.65% to $5.90. The company announced that its results for the second quarter ended June 30, 2013, will be released before the opening of the market on Wednesday, July 31, 2013.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares declined 4.67% to $108.82. Roche Holding AG (ROG) is seeking billions of dollars in financing for a potential takeover of orphan-drug maker Alexion Pharmaceuticals Inc. (ALXN) (ALXN), people with knowledge of the situation said on July 13.
Roche, the world’s largest maker of cancer medicines, has been in contact with Cheshire, Connecticut-based Alexion on and off for months, said another person, who asked not to be named because the process is private. There is no guarantee a deal will happen.
Additionally, the company will report its financial results for the second quarter ended June 30, 2013 on Thursday, July 25, 2013 before the US financial markets open. Following the release of the financial results, Alexion management will conduct a conference call and audio web cast on Thursday, July 25, 2013, at 10:00 a.m. Eastern Time (ET).
Rockwell Medical Inc. (NASDAQ:RMTI) shares jumped 9.04% to $5.67. The company, on July 11, said results were positive from a late-stage study of its investigational drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell, a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease, said SFP met the primary endpoint, demonstrating a statistically significant mean change in hemoglobin. Additionally, SFP met key secondary endpoints, including maintenance of hemoglobin, maintenance of reticulocyte hemoglobin, and increase in serum iron pre-to-post treatment without an increase in ferritin.
pSivida Corp. (NASDAQ:PSDV) stock jumped 4.74% to $3.54. The company on July 11 announced interim data from an investigator-sponsored Phase I/II study of pSivida's injectable micro-insert in patients with posterior uveitis. The same micro-insert is being marketed in the EU as ILUVIEN® for the treatment of chronic Diabetic Macular Edema (DME) considered insufficiently responsive to available therapies by pSivida's collaborative partner, Alimera Sciences. The uveitis application is being independently developed by pSivida.